Oxaliplatine Fresenius Kabi

Oxaliplatin, the active ingredient in Oxaliplatine Fresenius Kabi, is a platinum compound presented as a sterile solution for intravenous infusion. It is indicated for the management of selected solid tumours, chiefly colorectal and gastric cancers, and is used in adult patients as part of combination chemotherapy regimens.

GNH USA supplies Oxaliplatine Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and specialty pharmacies worldwide, ensuring consistent quality and regulatory conformity under European Union pharmacopeial standards.

Oxaliplatin is a platinum‑based chemotherapeutic agent used in the treatment of cancers that involve DNA cross‑linking pathways.

- Metastatic colorectal cancer: improves overall survival when combined with fluoropyrimidine and leucovorin. - Adjuvant treatment of stage III colon cancer: reduces risk of disease recurrence after surgical resection. - Advanced gastric cancer: provides disease control as part of combination therapy in patients unsuitable for surgery.

Oxaliplatin is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting - Peripheral neuropathy - Fatigue - Neutropenia

Serious or Rare Side Effects: - Severe allergic reactions (anaphylaxis) - Febrile neutropenia - Pulmonary toxicity (interstitial pneumonitis) - Cardiac arrhythmias

Prior to and during oxaliplatin therapy, careful monitoring and patient assessment are essential. - Renal function monitoring: assess creatinine clearance before each cycle. - Hepatic function monitoring: check liver enzymes and bilirubin regularly. - Neuropathy assessment: evaluate sensory changes and adjust dose if worsening. - Hypersensitivity risk: discontinue infusion if signs of severe allergic reaction appear. - Pregnancy and lactation: avoid use; drug may cause fetal harm and is excreted in breast milk. - Store at room temperature: keep in original container, protect from light and moisture.

Oxaliplatin may interact with other medicines, requiring vigilance to avoid additive toxicity.

Major Interactions (Avoid): - Concurrent use with other platinum agents: additive nephro‑ and neuro‑toxicity. - Combination with nephrotoxic drugs (e.g., aminoglycosides, cisplatin): increased risk of renal impairment. - Use with strong ototoxic agents (e.g., high‑dose aminoglycosides): heightened auditory toxicity.

Moderate Interactions (Monitor Closely): - Co‑administration with anticoagulants: monitor bleeding parameters. - Concomitant use with anti‑emetics (e.g., ondansetron): may improve tolerability but watch for QT prolongation. - Interaction with calcium or magnesium supplements: may reduce neurotoxicity; monitor electrolyte levels.